The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rehabilitation, Therapy Goals for Scleroderma, Acroosteolysis

Rehabilitation, Therapy Goals for Scleroderma, Acroosteolysis

May 15, 2015 • By Lauren Tarsi and Marie B. Corkery, PT, DPT, MHS, FAAOMPT

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Acroosteolysis of the hands in a patient with scleroderma.

Acroosteolysis of the hands in a patient with scleroderma.
Image Credit: Lauren Tarsi

Scleroderma is a rare rheumatologic auto­immune disease that affects the skin and can also affect other organs. Due to excess formation of scar tissue, blood flow to the extremities is decreased, primarily to the hands, and tissues often become hypoxic, resulting in sclerodactyly and proximal skin involvement.2 The incidence of scleroderma in the U.S. is 50–300 cases per 1 million, and it most commonly affects women from age 30–50.1

You Might Also Like
  • Living Well with Scleroderma
  • Targeted Therapy for Scleroderma Fibrosis
  • The Clinician’s Role in Rehabilitation Therapy
Explore This Issue
May 2015

There are two main types of scleroderma: localized and systemic. Localized scleroderma is a milder form of the disease, normally affecting the skin and less commonly, the muscles, joints and bones. Tightening of the skin usually occurs on the hands and face, and the skin often appears shiny.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Systemic scleroderma is a more severe and progressive form of the disease and can affect all internal organs, including the lungs, liver, heart, kidneys, esophagus and bowels. This type of scleroderma can be life threatening or may cause severe complications.1,3

Adaptive equipment fosters functional independence in activities of daily living: Finger splints facilitate use of a computer keyboard.

Adaptive equipment fosters functional independence in activities of daily living: Finger splints facilitate use of a computer keyboard.

There’s no cure for scleroderma; however, many patients benefit from physical and occupational therapy to address impairments commonly associated with the disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Acroosteolysis, Fatigue & Other Complications

Acroosteolysis, found in 20–25% of patients with systemic scleroderma, is a disease that causes a destructive lytic change to the distal phalanges, causing the bone to shorten (see Figure 1).2 On X-rays, the distal phalanges take the shape of a small pyramid or a flattened ridge.

One of the biggest limiting factors for patients with scleroderma is fatigue, either stemming from the disease itself or due to the side effects of medication.6,8 Fatigue can sometimes make routine activities of daily living (ADLs) difficult.6,11 Patients may not be able to work to the extent that they used to or will require additional time or more frequent rest breaks, depending on their occupational requirements.

This photo shows a key holder with a built-up handle.

This photo shows a key holder with a built-up handle.

Ulcers on the fingers and toes are a common problem and are evident in more than half of patients with scleroderma. These ulcers develop due to repeated microtrauma and increased use of the hands, underlying calcinosis and impaired blood flow.5 It’s critical that ulcers be managed immediately. Educating the patient to recognize and immediately report these ulcers is an important aspect of care. The longer the ischemia continues into the digits, the higher the risk that the ulcer won’t heal and, ultimately, will develop into a chronic ulcer.6

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Primary Therapy Goals

The main goal of therapy for patients with scleroderma is to retain range of motion. Because the skin can become taut, the patient may experience a permanent loss in range of motion.9

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: Acroosteolysis, patient care, rehabilitation, Scleroderma, therapyIssue: May 2015

You Might Also Like:
  • Living Well with Scleroderma
  • Targeted Therapy for Scleroderma Fibrosis
  • The Clinician’s Role in Rehabilitation Therapy
  • Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)